| Literature DB >> 30008706 |
Christina G Aas1,2, Finn Drabløs1, Kjersti Haugum1,2, Jan E Afset1,2.
Abstract
Shiga toxin-producing Escherichia coli (STEC) cause both sporadic infections and outbreaks of enteric disease in humans, with symptoms ranging from asymptomatic carriage to severe disease like haemolytic uremic syndrome (HUS). Bacterial virulence factors like subtypes of the Shiga toxin (Stx) and the locus of enterocyte effacement (LEE) pathogenicity island, as well as host factors like young age, are strongly associated with development of HUS. However, these factors alone do not accurately differentiate between strains that cause HUS and those that do not cause severe disease, which is important in the context of diagnosis, treatment, as well as infection control. We have used RNA sequencing to compare transcriptomes of 30 stx2a and eae positive STEC strains of non-O157 serogroups isolated from children <5 years of age. The strains were from children with HUS (HUS group, n = 15), and children with asymptomatic or mild disease (non-HUS group, n = 15), either induced with mitomycin C or non-induced, to reveal potential differences in gene expression levels between groups. When the HUS and non-HUS group were compared for differential expression of protein-encoding gene families, 399 of 6,119 gene families were differentially expressed (log2 fold change ≥ 1, FDR < 0.05) in the non-induced condition, whereas only one gene family was differentially expressed in the induced condition. Gene ontology and cluster analysis showed that several fimbrial operons, as well as a putative type VI secretion system (T6SS) were more highly expressed in the HUS group than in the non-HUS group, indicating a role of these in the virulence of STEC strains causing severe disease.Entities:
Keywords: HUS; STEC; T6SS; adherence; fimbriae; transcriptome; virulence
Year: 2018 PMID: 30008706 PMCID: PMC6033998 DOI: 10.3389/fmicb.2018.01416
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Characteristics of clinical and reference strains used in this study.
| Clinical strains | FHI63 | B1 | O145 | + | – | + | + | |
| FHI48 | B1 | O121 | + | – | + | + | ||
| FHI12 | B1 | O103 | + | – | + | + | ||
| FHI24 | B1 | O26 | + | – | + | + | ||
| FHI25 | B1 | O145 | + | – | + | + | ||
| FHI27 | B1 | O26 | + | + | + | + | ||
| FHI79 | B1 | O26 | + | – | + | + | ||
| FHI8 | B1 | O86 | + | – | + | + | ||
| FHI9 | B1 | O103 | + | – | + | + | ||
| FHI83 | B1 | O121 | + | – | + | + | ||
| FHI4 | B1 | O26 | + | – | + | + | ||
| FHI6 | B1 | O111 | + | + | + | + | ||
| FHI7 | B1 | O103 | + | – | + | + | ||
| St. Olav164 | B1 | O145 | + | – | + | + | ||
| St. Olav176 | B1 | O177 | + | – | + | + | ||
| St. Olav104 | B1 | O145 | – | – | + | + | ||
| FHI43 | B1 | O121 | – | – | + | + | ||
| FHI36 | B1 | O26 | – | – | + | + | ||
| FHI66 | B1 | OUT | – | + | + | + | ||
| FHI95 | E | O145 | – | – | + | + | ||
| St. Olav17 | B1 | O121 | – | + | + | + | ||
| St. Olav39 | B1 | OUT | – | + | + | + | ||
| St. Olav40 | B1 | OUT | – | + | + | + | ||
| St. Olav63 | B1 | O121 | – | – | + | + | ||
| St. Olav157 | B1 | O121 | – | – | + | + | ||
| St. Olav172 | E | O145 | – | – | + | + | ||
| St. Olav173 | E | O145 | – | – | + | + | ||
| St. Olav174 | B1 | O26 | – | – | + | + | ||
| St. Olav178 | B1 | O177 | – | – | + | + | ||
| St. Olav179 | B1 | O26 | – | – | + | + | ||
| Reference strains | 42 | D | O44 | – | – | – | – | |
| REL606 | A | O7 | – | – | – | – | ||
| ED1a | B2 | O81 | – | – | – | – | ||
| IAI1 | B1 | O8 | – | – | – | – | ||
| IAI39 | F | O7 | – | – | – | – | ||
| CB9615 | E | O55 | – | – | – | + | ||
| NRG 857C | B2 | O83 | – | – | – | – | ||
| 12009 | B1 | O103 | – | + | + | + | ||
| 2011C-3493 | B1 | O104 | + | – | + | – | ||
| Sakai | E | O157 | + | + | + | + | ||
| SMS-3-5 | F | O19 | – | – | – | – | ||
| K-12 MG1655 | A | O16 | – | – | – | – | ||
| UMN026 | D | O17 | – | – | – | – | ||
| UTI89 | B2 | O18 | – | – | – | – |
eae is used as a marker for the LEE pathogenicity island.
Figure 1Core genome phylogeny of clinical and reference strains. STEC strains associated with HUS are indicated by red stars, and phylogroups are colored according to the legend.
Figure 2Differentially expressed protein-encoding gene families between groups (HUS vs. non-HUS) and conditions (induced vs. non-induced). Statistically significant results (FDR < 0.05) are included, with expression shown as log2 fold change (y-axis) for each gene family (x-axis) (A) HUS vs. non-HUS (non-induced conditions), (B) HUS vs. non-HUS (induced conditions), (C) Induced vs. non-induced (non-HUS group), and (D) Induced vs. non-induced (HUS group).
Differentially expressed protein-encoding gene families.
| HUS vs. non-HUS | Unique for induced condition | 0 | 399 | 1 |
| Unique for non-induced condition | 165 | 1 | 234 | |
| Common for both conditions | 0 | 5319 | 0 | |
| Total | 165 | 5719 | 235 | |
| Induced vs. non-induced | Unique for HUS-group | 10 | 39 | 53 |
| Unique for non-HUS group | 12 | 63 | 27 | |
| Common for both groups | 5 | 5522 | 90 | |
| Total | 27 | 5624 | 170 | |
Differentially expressed gene families with 2-fold change or higher between groups (HUS vs. non-HUS) and conditions (induced vs. non-induced) are included.
Figure 3Gene ontologies of differentially expressed protein-encoding gene families in the HUS vs. non-HUS group. Biological process gene ontologies (y-axis) where the number of gene families assigned (x-axis) is higher than one are included. Subgroups (induced and non-induced condition) are colored according to the legend.
Identity and function of a selection of differentially expressed protein-encoding gene families between the HUS and non-HUS group.
| 4021 | 1.56 | Nucleic acid phosphodiester bond hydrolysis | Secreted protein Hcp | Type VI secretion system | 15 | 12 | |
| 3905 | 2.37 | NA | IcmF-related protein | Type VI secretion system | 15 | 12 | |
| 3990 | 2.05 | NA | Type VI secretion protein VasI | – | Type VI secretion system | 15 | 12 |
| 3907 | 2.37 | Proteolysis | ClpB protein | Type VI secretion system | 15 | 12 | |
| 58 | 2.99 | NA | VgrG protein | Type VI secretion system | 15 | 12 | |
| 99 | 3.00 | Cellular response to phosphate starvation, dephosphorylation, cellular response to anoxia | core protein | – | Rhs protein | 15 | 12 |
| 23 | 3.04 | Transposition, DNA-mediated | Mobile element protein | – | – | 15 | 12 |
| 3790 | −2.97 | Pathogenesis | Probable glutamate/gamma-aminobutyrate antiporter | – | – | 13 | 15 |
| 3860 | 1.31 | Cell adhesion | type 1 fimbrae adaptor subunit FimF | F9 fimbriae | 15 | 13 | |
| 215 | 1.39 | Oxidation-reduction process | Mobile element protein | Z4324 | OI-122 | 15 | 14 |
| 611 | 1.19 | Oxidation-reduction process | Enterotoxin | OI-122 | 15 | 14 | |
| 4065 | 2.48 | NA | FIG00638171: hypothetical protein | EDL933_4193 | OI-122 | 15 | 12 |
| 3569 | 1.25 | NA | FIG00638856: hypothetical protein | OI-122 | 15 | 14 | |
| 2325 | 1.08 | Oxidation-reduction process | Unknown function | OI-122 | 15 | 14 | |
| 3869 | −1.63 | Oxidation-reduction process, response to stress | Type III secretion chaperone protein for YopD (SycD) | – | – | 13 | 15 |
| 3865 | 1.32 | NA | PilT | – | – | 15 | 13 |
| 4042 | 1.76 | NA | FIG01200701: hypothetical protein | Yqi-like fimbriae | 15 | 12 | |
| 4014 | 2.15 | Cell adhesion | Uncharacterized fimbrial-like protein ygiL precursor | Yqi-like fimbriae | 15 | 12 | |
| 3912 | 2.36 | Transport | Uncharacterized outer membrane usher protein yqiG precursor | Yqi-like fimbriae | 15 | 12 | |
| 3908 | 2.98 | NA | Alpha-fimbriae usher protein | – | Cs1-like fimbriae | 15 | 12 |
| 4017 | 1.94 | NA | Alpha-fimbriae major subunit | – | Cs1-like fimbriae | 15 | 12 |
| 4010 | 1.99 | Cell adhesion | Putative fimbrial-like protein | Yra fimbriae | 15 | 12 | |
| 3997 | 1.93 | Pilus organization | Chaperone protein fimC precursor | Yra fimbriae | 15 | 12 | |
| 3911 | 2.45 | Transport | type 1 fimbriae anchoring protein FimD | Yra fimbriae | 15 | 12 | |
| 2526 | −1.16 | Oxidation-reduction process, response to oxidative stress, negative regulation of transcription, DNA-templated | Flavoprotein wrbA | – | Insertion site of Stx phage | 15 | 15 |
| 62 | 1.05 | NA | putative virulence protein | IS609 transposase B | 15 | 14 | |
| 90 | 2.08 | Transposition, DNA-mediated | Mobile element protein | IS609 transposase A | 15 | 13 | |
| 2890 | −1.14 | Cell adhesion | Universal stress protein F | Insertion site of phage | 15 | 15 | |
| 3840 | 1.18 | NA | HTH-type transcriptional regulator mlrA | Insertion site of Stx phage | 15 | 13 | |
| 4012 | 1.90 | Cell adhesion | Major fimbrial subunit StfA | Yfc fimbriae | 15 | 12 | |
| 3849 | 1.55 | Regulation of transcription, DNA-templated, transcription, DNA-templated, DNA integration, DNA recombination | type 1 fimbriae regulatory protein FimE | type-1-fimbriae | 15 | 13 | |
| 3856 | 2.29 | Cell adhesion | type 1 fimbriae major subunit FimA | type-1-fimbriae | 15 | 13 | |
| 3858 | 1.68 | Cell adhesion | type 1 fimbriae protein FimI2C unknown function | type-1-fimbriae | 15 | 13 | |
| 3841 | 1.72 | Pilus organization | chaperone FimC | type-1-fimbriae | 15 | 13 | |
| 1 | 1.13 | NA | Mobile element protein | – | type-1-fimbriae | 15 | 14 |
| 3859 | 1.62 | Cell adhesion | type 1 fimbrae adaptor subunit FimF | type-1-fimbriae | 15 | 13 | |
| 3863 | 1.40 | Cell adhesion, pilus organization | type 1 fimbrae adaptor subunit FimG | type-1-fimbriae | 15 | 13 | |
| 3822 | 1.67 | Cell adhesion | mannose-specific adhesin FimH | type-1-fimbriae | 15 | 13 | |
| 4106 | −2.51 | Cell adhesion | FIG01069793: hypothetical protein | – | – | 11 | 15 |
| 3624 | −1.04 | Pathogenesis | Methionine aminopeptidase (EC 3.4.11.18) | – | – | 14 | 15 |
| 4040 | 2.12 | Nucleic acid phosphodiester bond hydrolysis | CRISPR-associated protein2C Cas2 | CRISPR/Cas | 15 | 12 | |
| 3964 | 2.24 | nucleic acid phosphodiester bond hydrolysis, defense response to virus, maintenance of CRISPR repeat elements | CRISPR-associated protein Cas1 | CRISPR/Cas | 15 | 12 | |
| 4003 | 2.18 | NA | CRISPR-associated protein2C Cse3 family | CRISPR/Cas | 15 | 12 | |
| 3989 | 1.94 | Defense response to virus | CRISPR-associated protein2C CT1976 | CRISPR/Cas | 15 | 12 | |
| 3950 | 2.09 | NA | CRISPR-associated protein2C Cse4 family | CRISPR/Cas | 15 | 12 | |
| 4172 | 3.31 | Cell adhesion | Fimbriae-like adhesin SfmA | – | LPFB1 fimbriae | 15 | 10 |
| 4168 | 3.45 | Pilus organization | Putative fimbrial chaperone protein | – | LPFB1 fimbriae | 15 | 10 |
| 4158 | 4.21 | Transport | type 1 fimbriae anchoring protein FimD | – | LPFB1 fimbriae | 15 | 10 |
| 4163 | 3.59 | Cell adhesion | Putative fimbrial protein | – | LPFB1 fimbriae | 15 | 10 |
| 3639 | −1.07 | Pathogenesis | Phosphate transport system regulatory protein PhoU | – | – | 14 | 15 |
| 3451 | 1.52 | Pathogenesis | FIG00638466: hypothetical protein | – | – | 15 | 14 |
| 3588 | 1.06 | Chemotaxis, archaeal, or bacterial-type flagellum-dependent cell motility | Flagellar motor rotation protein MotB | – | – | 15 | 14 |
| 4011 | 1.61 | Cell adhesion | Uncharacterized fimbrial-like protein ygiL precursor | Ybg fimbriae | 15 | 12 | |
| 3913 | 2.34 | Transport | Uncharacterized outer membrane usher protein yqiG precursor | Ybg fimbriae | 15 | 12 | |
| 3991 | 1.98 | Pilus organization | Periplasmic fimbrial chaperone | Ybg fimbriae | 15 | 12 | |
| 3953 | 2.03 | Cell adhesion | FIG00637862: hypothetical protein | Ybg fimbriae | 15 | 12 | |
| 23 | 3.04 | Transposition, DNA-mediated | Mobile element protein | DDE domain transposase family | 15 | 12 | |
| 4242 | 4.23 | NA | orf2C hypothetical protein | putative secreted protein | 15 | 9 | |
| 68 | 8.49 | NA | core protein | Rhs protein | 15 | 5 | |
Differential expression is shown as log2 fold change. Identification and putative functions are based on gene ontology, annotation and blast against E. coli reference genomes and virulence factor databases.
Figure 4Gene ontologies of differentially expressed protein-encoding gene families in the induced vs. non-induced condition. Biological process gene ontologies (y-axis) where the number of gene families assigned (x-axis) is higher than one are included. Subgroups (HUS and non-HUS) are colored according to the legend.